| Literature DB >> 34491551 |
Aleksandra Kaliszewska1, Joseph Allison1, Tarik-Tarkan Col1, Christopher Shaw1,2, Natalia Arias3,4.
Abstract
A hexanucleotide repeat expansion in the C9orf72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) with synaptic dysfunction identified as an early pathological hallmark. Although TDP-43 pathology and overt neurodegeneration are largely absent from the cerebellum, the pathological hallmarks of RNA foci and dipeptide repeat protein (DPR) inclusions are most abundant. Here, we present a systematic literature search in the databases of PubMed, Scopus, Embase, Web of Science and Science Direct up until March 5, 2021, which yielded 19,515 publications. Following the exclusion criteria, 72 articles were included having referred to C9orf72, synapses and the cerebellum. Meta-analyses were conducted on studies which reported experimental and control groups with means and standard deviations extracted from figures using the online tool PlotDigitizer. This revealed dendritic defects (P = 0.03), reduced C9orf72 in human patients (P = 0.005) and DPR-related neuronal loss (P = 0.0006) but no neuromuscular junction abnormalities (P = 0.29) or cerebellar neuronal loss (P = 0.23). Our results suggest that dendritic arborisation defects, synaptic gene dysregulation and altered synaptic neurotransmission may drive cerebellar synaptic dysfunction in C9-ALS/FTD. In this review, we discuss how the chronological appearance of the different pathological hallmarks alters synaptic integrity which may have profound implications for disease progression. We conclude that a reduction in C9orf72 protein levels combined with the accumulation of RNA foci and DPRs act synergistically to drive C9 synaptopathy in the cerebellum of C9-ALS/FTD patients.Entities:
Keywords: ALS; C9orf72; Cerebellum; FTD; Synaptic dysfunction
Mesh:
Substances:
Year: 2021 PMID: 34491551 PMCID: PMC9325807 DOI: 10.1007/s12311-021-01320-0
Source DB: PubMed Journal: Cerebellum ISSN: 1473-4222 Impact factor: 3.648
Fig. 1Putative mechanisms underlying synaptic dysfunction in C9orf72-ALS/FTD. A schematic detailing the role of the hexanucleotide expansion, (G4C2)n, of the C9orf72 gene in driving synaptic, axonal and dendritic dysfunction. This operates through the three main pathogenic mechanisms implicated in C9-ALS/FTD which are haploinsufficiency of the C9orf72 protein and the accumulation of RNA foci and dipeptide repeats (DPRs). Abbreviations: p53, tumour protein p53; RAN, repeat-associated non-AUG; Ca, calcium ions; mRNP, messenger ribonucleoprotein; RNA, ribonucleic acid
Overview of the studies included for meta-analysis
| Study | Included? | Figure chosen | Relevant meta-analysis | Comment |
|---|---|---|---|---|
| Herranz-Martin et al. [ | Yes | Fig. S2D | Cerebellar neuronal loss | Purkinje cell counts between HRE-10 (disease control) and HRE-102 |
| Tan et al. [ | Yes | Table | Cerebellar neuronal loss | Spino- and Cerebro-cerebellum were averaged for Purkinje cells — other studies did not state a specific area of the cerebellum; therefore, both were included to avoid bias |
| Hao et al. [ | Yes | Figure | Cerebellar neuronal loss; DPR-related neuronal loss | Purkinje counts across an age range (averaged over time) comparing poly-PR with controls. Figure |
| Zhang et al | Yes | Fig. S3G | Cerebellar neuronal loss; DPR-related neuronal loss | Purkinje cell counts between GFP and poly-PR. Time points were averaged |
| May et al. [ | Yes | Figure | Dendritic arborisations | Number of dendritic crossings. All distances from the soma of dendritic crossings were averaged to give a total effect across the neuron |
| Park et al. [ | Yes | Figure | Dendritic arborisations | Number of dendritic branch points under different DPR transgenes (DPR effect was averaged) |
| Schweizer Burguete et al. [ | Yes | Fig. S4B | Dendritic arborisations | Shows late control versus late experimental of dendritic crossings. Preferred to Fig. |
| LaClair et al. [ | Yes | Figure | DPR-related neuronal loss | Figure |
| Darling et al. [ | Yes | Figure | DPR-related neuronal loss | All DPRs were averaged to compare against the control. Cell viability of iPSCs was assessed |
| Zhang et al. [ | Yes | Figure | DPR-related neuronal loss | Score of hippocampal neuronal loss — time points were averaged |
| Xu and Xu [ | Yes | Figure | NMJ abnormalities | Total bouton counts |
| Perry et al | Yes | Figure | NMJ abnormalities | Total bouton counts. (G4C2)8 was averaged as a control, whilst (G4C2)58 and GR36/100 were averaged as experimental |
| Freibaum et al. [ | Yes | Figure | NMJ abnormalities | Total bouton counts — control and (G4C2)8 were averaged as this is to represent disease control |
| Frick et al. [ | Yes | Figure | Reduced C9orf72 | Normalised C9orf72 levels in the cerebellum |
| Saberi et al | Yes | Figure | Reduced C9orf72 | Normalised C9orf72 levels in the frontal cortex (chosen over occipital cortex) |
| Belzil et al. [ | Yes | Figure | Reduced C9orf72 | Normalised C9orf72 levels in the frontal cortex (chosen over CB due to frontal cortex being more widely studied) |
| Waite et al. [ | Yes | Figure | Reduced C9orf72 | Normalised C9orf72 levels in the frontal cortex (C9-ALL was chosen over specific variants) |
| Yang et al. [ | No | Figure | Dendritic arborisations | Not included as only the number of neurons counted were given, not the number of animals per genotype (such as other studies) which would skew the weighting |
| Park et al | No | Figure | Neurite length | Dendritic length — |
| Zhang et al. [ | No | Fig. S5B | Neurite length | No sample sizes were given — unable to calculate confidence intervals |
| Swaminathan et al | No | Figure | Neurite length | Neurite length meta-analysis |
Studies that are italicised had their means multiplied by − 1 as these studies measured negative effects but as a percentage (an increase in percentage is a negative outcome) and therefore were brought in line with the other studies. Abbreviations: HRE, hexanucleotide repeat expansion; GFP, green fluorescent protein; DPR, dipeptide repeat protein; NMJ, neuromuscular junction; iPSCs, induced pluripotent stem cells
Fig. 2Inclusion of articles by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram
Publications retrieved concerning synaptic function and morphology
| Study | Methodology | Main findings |
|---|---|---|
| Bieniek et al. [ | FTD- PCR, Thioflavin-S staining, IHC and IF | |
| Devlin et al. [ | Patient-derived iPSC MNs with RNA FISH, IF, repeat PCR, electrophysiology and cell viability assays | |
| Freibaum et al. [ | Transgenic | |
| Frick et al | Post-mortem tissue from ALS/FTD/ALS-FTD patients with Generation and characterisation of novel monoclonal antibodies against C9orf72; ICC, IF and biochemistry techniques to detect, quantify and co-localise C9 protein | |
| Hao et al. [ | Transgenic mouse model expressing poly-PR under the control of neuronal Histopathological, behavioural, RNA sequencing and gene ontology analysis | |
| Herranz-Martin et al | Two mouse lines overexpressing either 10 pure or 102 interrupted G4C2 repeats mediated by AAV viral injection (i.e. HRE-10 and HRE-102 mice) Mouse behavioural testing, RNA FISH to detect intracellular RNA foci, IF, immunoblotting | Poly-GA aggregates were widespread in the cerebellum of HRE-102 but not HRE-10 mice, accompanied by high expression of p62 |
| Jensen et al. [ | 20-month old transgenic mouse line expressing poly-GA149; Transfected primary rat cortical and motor neurons with poly-GA; Patient-derived Immunocytochemistry, immunoblotting and IHC; live-cell imaging, qRT-PCR | |
| LaClair et al | Double transgenic mouse lines (poly-GA-Nes and -PR-Nes) generated by crossing poly-GA175 and GFP-PR175 mice (expressing poly-GA and poly-PR) with Nestin-Cre driver line to allow for CNS-wide neuronal high-level expression of the two key DPRs Quantitative ICC and IF of DPRs and NeuN-positive cells; Western blotting, ELISA, qPCR and gene ontology | |
| Lee et al. [ | HEK-293 cells transfected with vectors containing 125 repeats of DPRs; chick embryos expressing DPR constructs; chick embryos electroporated with G4C2 constructs (8x, 38x, 72 × and 128); post-mortem tissue from IF staining; FISH; Western blotting; filter trap assay; TUNEL toxicity assay | |
| Mackenzie et al. [ | IHC, IF and haematoxylin and Eosin staining, immunoblotting, filter trap assays | |
| Maor-Nof et al. [ | Wild-type and p53-knockout Mouse primary cortical neurons were transduced with poly-PR50; Poly-PR50 mouse model; (G4C2)30 expressing IF, fly-eye degeneration assay, survival assay, comet assay, immunoblotting, ATAC-sequencing, RNA-sequencing, CRISPR-Cas9 | |
| May et al | Primary neuronal cell culture and HEK293 in vitro cultures transfected with constructs encoding synthetic genes for DPRs in the absence of G4C2 repeats; post-mortem tissue from Analysis of DPR toxicity and aggregation properties; quantitative mass spectrometry to identify co-aggregates of Poly-GA | |
| O’Rourke et al. [ | Transgenic mice carrying bacterial artificial chromosome (BAC) containing human FISH of sense and antisense RNA foci; immunostaining of DPRs; behavioural testing; histological examination of neuronal and motor damage; RNA-seq analysis | |
| Park et al | Analysis of dendritic length and branching points of class IV dendritic arborisation (C4 da) neurons, RT-PCR analysis of CrebA mRNA levels | |
| Perry et al | IF, electrophysiology and behavioural assays | |
| Saberi et al | Post-mortem brain and spinal cord tissue of C9-ALS patients Quantitative analysis of DPRs, nuclear pore proteins and C9orf72 protein | |
| Sellier et al. [ | Mouse cortical neurons were transduced with shRNA against IF, immunoprecipitation, Western blot, novel antibody manufacture, behavioural studies, gross morphological analysis | |
| Schweizer Burguete et al. [ | (G4C2)48 repeat transduced Live imaging, FISH, immunofluorescence | |
| Swaminathan et al. [ | Zebrafish model transiently expressing constructs containing DPRs of varying lengths (40, 200 and 1000); transgenic zebrafish line expressing 100 repeats of poly-GR Touch-evoked escape response test; Western blotting; acridine orange staining; assessment of motor neuron morphology | |
| Xiao et al. [ | Immunoprecipitation, electrophoresis and immunoblotting, IF, synaptosome fragmentation | |
| Xu and Xu [ | UAS-DPR Behavioural assays and lifespan assay; immunoblotting and IHC, live imaging, qPCR, drug treatment | |
| Yang et al. [ | Transgenic Fly wing notching phenotyping; climbing assay and quantification of dendritic branching; IHC, qRT-PCR | |
| Zhang et al | Cultured cells and primary neurons transfected with GFP-GA50, GFP-GP47, GFP-GR50, GFP-PR50 or GFP-PA50 expression vectors; post-mortem tissue from C9-ALS/FTD cases IHC; electron microscopy; immune-electron microscopy; FISH; live cell imaging; Western blot; qRT-PCR |
Abbreviations: AAV, adeno-associated virus; ALS, amyotrophic lateral sclerosis; ATAC, assay for transposase-accessible chromatin; Ca, calcium ions; CA3, Cornu Ammonis 3; Cas9, CRISPR-associated protein 9; CNS, central nervous system; CrebA, cyclic AMP response element binding protein A; CRISPR, clustered regularly interspaces short palindromic repeats; DPRs, dipeptide repeats; ELISA, enzyme-linked immunosorbent assay; ER, endoplasmic reticulum; FISH, fluorescent in-situ hybridisation; FTD, frontotemporal dementia; GDP, guanosine diphosphate; GFP, green fluorescent protein; GluR1, glutamate receptor 1; GTP, guanosine triphosphate; HEK293T, human embryonic kidney cells; hnRNP, heterogenous nuclear ribonucleoproteins; HRE, hexanucleotide repeat expansions; ICC, immunocytochemistry; IF, immunofluorescence; IHC, immunohistochemistry; iPSC, induced pluripotent stem cells; K+, potassium ions; KO, knockout; MNs, motor neurons; Na+, sodium ions; NeuN, neuronal nuclei; NMJ, neuromuscular junction; p53, tumour protein 53; p62, ubiquitin-binding protein; PCR, polymerase chain reaction; PUMA, p53 upregulated modulator of apoptosis; Pur-α, purine-rich element binding protein; qRT-PCR, quantitative real-time PCR; RAB, ras-associated binding; RNA, ribonucleic acid; shRNA, small hairpin RNA; SMCR8, Smith-Magenis syndrome chromosomal region candidate gene 8; SOD1, superoxide dismutase 1; TARDBP, Tar-DNA binding protein; TDP-43, Tar-DNA binding protein 43; Thy1, thymocyte differentiation antigen 1; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labelling; UAS, upstream activation sequence; WDR41, WD repeat domain 41
Publications retrieved concerning findings in the cerebellum
| Study | Methodology | Main findings |
|---|---|---|
| Al-Sarraj et al | Post-mortem tissue from MND/ALS, FTLD and ALS-FTLD cases with, and FTLD cases without C9 expansion mutation Neuropathological assessment, IHC and IF studies | |
| Ash et al. [ | Human Meso scale discovery assay, IHC, IF; generation of novel antibodies to poly-GA, GP and -GR | |
| Belzil et al. [ | qRT-PCR, ddPCR and chromatin immunoprecipitation | |
| Chew et al | Transgenic mouse model expressing (G4C2)66 throughout the CNS by means of AAV-mediated somatic brain transgenesis Behavioural testing; RNA FISH detection of RNA foci, immunoassays for DPRs | |
| Cooper-Knock et al | Samples from ALS/FTD cases with and without C9 expansion mutation, healthy controls and asymptomatic C9 carriers Identification of nuclear and cytoplasmic RNA foci using FISH, investigation of RNA foci binding partners using mass spectrometry, pulldown assays and IHC | |
| Cooper-Knock et al. [ | IHC, FISH, RNA-binding assays | |
| Corcia et al | Case study report | |
| Davidson et al. [ | Post-mortem tissue from FTLD-tau, FTLD-TDP type A, B and C, and IHC staining and pathological assessment | |
| Davidson et al. [ | IHC, antibody comparison | |
| DeJesus-Hernandez et al | Cerebellum and frontal cortex tissue of C9 expansion mutation carriers Detection and visualisation of RNA foci by RNA FISH and IF staining followed by computer-assisted quantification and co-localisation | |
| Fogel et al | Adult-onset sporadic ataxia cases Ataxia patients were screened for common genetic spinocerebellar ataxias and tested for | |
| Gendron et al | Post-mortem tissue from ALS, FTLD, MND and neurodegenerative disease with and without C9 mutation; HeLa cells and HEK293T cells transfected with either (C4G2)66 or (C4G2)2 expression vectors Generation of novel antibodies to visualise C4G2 RAN proteins – poly-PR, -GP and -PA, FISH to detect RNA foci formed from antisense transcripts in cultured cells, FISH detection of RNA foci and IF staining of human post-mortem tissue | |
| Gendron et al | Post-mortem tissue from Quantitative immunoassays; IHC; analysis of patients’ clinical data | |
| Goldman et al | Family with multiple system atrophy (MSA) and ALS, positive for C9 expansion mutation Case study report | |
| Lee et al | (G4C2)n transfected human non-neuronal cell lines and rat primary cortical neurons; zebrafish embryos injected with EGFP constructs containing 8x, 38 × and 72 × G4C2 repeats; human cerebellum tissue from ALS and FTD cases with confirmed C9 expansion mutation Detection of RNA foci by FISH, immunoprecipitation, FACS and ICC analysis for expression of apoptosis markers, detection and co-localisation of DPRs | |
| Mackenzie et al. [ | Cohort of 35 cases with a broad spectrum of clinical phenotypes, positive for Characterised novel monoclonal antibodies against poly-GA; immunoblotting | |
| Mahoney et al. [ | Cases with Clinical, histopathological and neuroimaging analysis of C9orf72 expansion mutation | |
| Mann et al. [ | Post-mortem tissue from IHC; southern blotting | |
| Mizielinska et al | Post-mortem tissue from C9-FTLD cases, neurodegenerative disease and healthy controls FISH and protein immuno-staining to detect, quantify and determine the subcellular localisation of sense and antisense RNA foci | |
| Mori et al. [ | Post-mortem tissue from Generation of novel antibodies against antisense-translated DPRs and putative carboxy-terminal tails of poly-GP, -GR and -GA reading frames; IHC analysis; ELISA and immunoblotting | |
| Quaegebeur et al. [ | Brain homogenates of FTD patients with Meso scale discovery (MSD) immunoassay | |
| Renton et al | ALS-FTD cases with a positive linkage to the chromosome 9p21 region Next-generation sequencing of chromosome 9p21 region; FISH analysis; expression arrays; RT-PCR | |
| Schludi et al. [ | Transgenic mice expressing (poly-GA)149 conjugated with cyan fluorescent protein (CFP) under the control of Thy1 promotor — Thy1 (GA)149-CFP mice; post-mortem IHC and IF staining, immunoassays; qRT-PCR; behavioural and clinical assessment of mouse motor function | |
| Tan et al. [ | ALS and FTLD cases mostly without the Cognitive, neuropsychiatric and functional assessment of patients; neuroimaging data | |
| Tan et al | Post-mortem cerebellum tissue from Histopathological analysis of cerebellar Purkinje and granule cell integrity | |
| Troakes et al. [ | Case study, IHC, Western blot | |
| van Blitterswijk et al | Post-mortem cerebellar and/ or frontal cortex tissue from qRT-PCR and digital molecular barcoding techniques to assess total C9 transcript and variant (1–3) levels; immunoassay of DPRs | |
| Waite et al | Subjects with confirmed diagnosis of ALS, FTLD or ALS-FTD Southern blot detection of | |
| Xiao et al | Post-mortem tissue from ALS cases with confirmed C9orf72 mutation, non-C9-ALS cases and healthy control Development of novel antibodies against C9-L and C9-S isoforms of C9orf72; investigation of the properties, abundance and subcellular localisation of C9 isoforms using IHC, Western blotting and immunoprecipitation | |
| Zhang et al. [ | Transgenic mouse model expressing GFP-(GR)100 in the brain; transfected HEK293T cells expressing GFP-(GR)100 constructs; post-mortem cerebellar and cortical tissue from C9-ALS/FTD patients Mouse behavioural test; IHC and IF staining; Western blot; FISH; RNA-Seq and gene ontology; qPCR; RT-PCR; in vivo SUnSET assay | |
| Zhang et al. [ | Mouse model expressing poly-PR mediated through AAV1 viral injection of GFP-PR50; post-mortem frontal cortical tissue from ALS and FTD cases with C9 mutation; human iPSC-derived neurons Mouse behavioural testing, histopathological analysis, RNA, protein and IHC and IF analysis, gene ontology |
Abbreviations: AAV, adenovirus; ALS, amyotrophic lateral sclerosis; ALYREF, Aly/REF export factor; ATXN2, Ataxin-2; ddPCR, droplet digital PCR; DPR, dipeptide protein; EGFP, enhanced green fluorescent protein; ELISA, enzyme-linked immunosorbent assay; FACS, fluorescence-activated cell sorting; FISH, fluorescent in-situ hybridization; FTD, frontotemporal dementia; FTLD, frontotemporal lobar dementia; GRN, progranulin; HEK293T, human embryonic kidney 293 cells; hnRNP, heterogeneous nuclear ribonucleoproteins; ICC, immunocytochemistry; IF, immunofluorescence; IHC, immunohistochemistry; iPSCs, induced pluripotent stem cells; MAPT, microtubule-associated protein Tau; MND, motor neuron disease; p62, ubiquitin binding protein p62; p-TDP-43, phosphorylated TAR-DNA binding protein 43; qRT-PCR, quantitative real time PCR; Rad23b, UV excision repair protein homolog B; RAN, repeat-associated non-AUG; RNA, ribonucleic acid; RNA-Seq, RNA sequencing; RT-PCR, real time PCR; SRSF2, serine and arginine rich splicing factor 2; SUnSET, surface sensing of translation; TDP-43, TAR-DNA binding protein 43; Unc119, uncoordinated 119
Publications retrieved concerning C9orf72-related pathology
| Study | Methodology | Main findings |
|---|---|---|
| Atanasio et al. [ | Behavioural and clinical examination of motor function; H&E and IHC analysis; RNA-seq | |
| Darling et al. [ | NSC34 cells transfected with DPR-containing plasmids; primary mouse neurons IF; Western blot; isothermal titration calorimetry (ITC); circular dichroism (CD) spectroscopy; fluorescence spectroscopy; dynamic light scattering (DLS); nanoparticle tracking analysis; transmission electron microscopy (TEM) | |
| DeJesus-Hernandez et al. [ | Patients with a PCR and qPCR, g/cDNA sequencing, western blotting, IHC and FISH | |
| Farg et al. [ | Neuronal cell lines — murine neuro2a and human SH-SY5Y transfected with IF and immunoblotting to investigate subcellular localisation of C9orf72 protein; ICC, IHC and immunoprecipitation to detect co-localisation of C9 protein with Rabs; siRNA transfection of SH-SY5Y cells; transfection of neuro2a cell lines with C9orf72-GFP and LC3; mass spectroscopy to identify C9-interacting proteins | |
| Koppers et al. [ | Conditional IHC analysis of motor neurons and neuromuscular junction integrity, gliosis and TDP-43 inclusions; FISH, Western blotting; motor function testing | |
| Lopez-Gonzalez et al. [ | Transgenic Genetic modifier screen; | |
| Mehta et al. [ | BaseScope™ ISH | |
| Mizielinska et al. [ | Northern blotting, FISH, Immunoblotting, egg-adult viability, eye phenotyping, lifespan assay | |
| Mori et al | Filter trap assay; immunoblotting; RT-PCR; qPCR; IHC; IF | |
| Mori | HEK293 cells transfected with plasmids containing 7, 17 or 23 repeats of G4C2; in vitro transcription of RNA probes; post-mortem tissue from LC–MS identification and quantification of proteins; Western blotting; IF and IHC | |
| Rudich et al. [ | Detection of DPRs by fluorescence microscopy; FRAP studies; paralysis and thrashing assays; brood size assays; neurodegeneration assays | |
| Schludi et al. [ | Transfected rat primary neuronal cultures expressing GA175, GR149, GP80 or PR175; post-mortem brain and spinal cord tissue from IHC; RNA FISH; quantitative analysis of inclusion pathology | |
| Sudria-Lopez et al. [ | Histopathological analysis | |
| Wen et al. [ | Rat primary cortical and motor neuron cultures transfected with PR50 cDNA and IHC; quantification of nucleoli and P-bodies | |
| Yamakawa et al | Synthetic cDNA encoding 100 repeats of poly-GA, poly-GP, poly-GR, poly-PR and poly-PA, without G4C2 repeats, was used to study the effects of those DPRs on transfected cultured neuronal cell lines (HeLa and HEK293) in vitro and mouse cortical neurons IHC, IF and immunoblot detection and characterisation of DPRs in cells, in utero electroporation, IHC of brain slices | |
| Zhang et al. [ | Western blot; electrophysiological recording; RNA FISH; IF, IHC and Phalloidin staining; FRAP analysis; electrophoretic mobility shift assays | |
| Zhang et al. [ | Transgenic mouse model expressing 50 repeats of poly-GA by means of AAV1 viral injection; primary neuronal cultures; HEK293T cells transfected with GFP-(GA)50; post-mortem tissue from C9-ALS cases IHC; IF; immunoelectron microscopy; quantification of neuropathology; silver staining; RT-qPCR; co-immunoprecipitation; immunoblotting; mouse behavioural testing | |
| Zu et al. [ | HEK293T cells transfected with antisense (G-2C4)40/50; IF, IHC, FISH, Western blot, protein dot blot, cell toxicity and viability assays, RT-PCR |
Abbreviations: ALS, amyotrophic lateral sclerosis; ATM, ataxia telangiectasia mutated; Cas9, CRISPR-associated 9; cDNA, circular DNA; CRISPR, clustered regularly interspaced short palindromic repeats; DPR, dipeptide repeat; ELISA, enzyme-linked immunosorbent assays; FISH, fluorescent in-situ hybridisation; FRAP, fluorescence recovery after photobleaching; FTD, frontotemporal dementia; Gal4, galactose 4; GFP, green fluorescent protein; GMR, glass multiple reporter; H&E, haematoxylin and eosin; HEK293, human embryonic kidney cells; hnRNP, heterogenous nuclear ribonucleoproteins; HR23, UV excision repair protein RAD23 homolog B; ICC, immunocytochemistry; IF, immunofluorescence; IHC, immunohistochemistry; iPSC, induced pluripotent cells; ISH, in situ hybridisation; Ku80, Lupus Ku autoantigen protein p80; lacZ, lactose operon Z; LC3, microtubule-associated proteins 1A/1B light chain 3B; LC–MS, liquid chromatography mass spectrometry; MND, motor neuron disease; NSC-34, motor neuron-like hybrid line; p53, tumour protein 53; p62, ubiquitin-binding protein; PCR, polymerase chain reaction; qPCR, quantitative polymerase chain reaction; Rab, ras-associated binding protein; RNA, ribonucleic acid; RNP, ribonucleoprotein; RT-PCR, real-time PCR; sdRNA, small self-deliverable interference RNA; shRNA, short hairpin RNA; siRNA, small interfering RNA; TDP-43, tar-DNA binding protein 43; TM6B, third chromosome balancer; UAS, upstream activation sequence; Unc119, uncoordinated 119
Fig. 3Frequency graphs illustrating the characteristics of selected studies. (A) Shows the number of studies that report synaptic dysfunction. (B) Illustrates the number of studies which report ALS/FTD pathology in C9-patients. (C) Shows the number of different animal models used in in vivo experiments. (D) Shows the number of different in vitro models used in the selected studies. (E) illustrates the pathomechanism type assessed in different animal models. (F) Illustrates the number of DPR constructs introduced to different animal models. Abbreviations: DPRs, dipeptide repeat proteins; NMJ, neuromuscular junction; cDNA, circular DNA
Fig. 4Meta-analysis using a random effects model of selected studies relating to synaptic deficits. (A) Shows the meta-analysis for dendritic defects assessing reductions in arborisations such as crossings and branchpoints (P = 0.03). (B) Shows the meta-analysis for neuromuscular junction (NMJs) abnormalities assessing synaptic bouton counts and fractured NMJs (P = 0.29). (C) Shows the meta-analysis for reductions of C9orf72 protein in human patients using frontal cortex and cerebellar samples (P = 0.005). All studies were highly heterogenous (I2 ≥ 84%; P ≤ 0.0004). The figure was generated using the RevMan 5.4 software. Abbreviations: SD, standard deviation; CI, confidence interval
Fig. 5Meta-analysis using a random effects model of selected studies relating to neuronal loss in C9orf72. (A) Shows the meta-analysis of neuronal loss in the cerebellum as a result of G4C2 repeats and DPR models (P = 0.23). (B) Shows the meta-analysis of DPR-related neuronal loss using animal models transfected with DPR constructs (P = 0.0006). Studies were highly heterogenous (I2 78%; P ≤ 0.001). The figure was generated using RevMan 5.4. Abbreviations: SD, standard deviation; CI, confidence interval
Data table for neurite length meta-analysis
| Study or subgroup | Control | Experimental | Std. mean difference IV, random, 95% CI | |||||
|---|---|---|---|---|---|---|---|---|
| Mean | SD | Total | Mean | SD | Total | Weight | ||
| Park 2020 | − 21,200.42 | 688.9353 | 6 | − 9,966.0752 | 806.3674322 | 6 | 43.7% | − 13.83 [− 20.67, − 6.98] |
| Swaminathan 2018 | − 195.9627 | 8.074534 | 7 | − 161.95652 | 5.74534162 | 7 | 56.3% | − 4.54 [− 6.79, − 2.30] |
| Zhang 2014 | − 266.422 | 17.61468 | 0 | − 125.77982 | 20.36697248 | 0 | Not estimable | |
| Total (95% CI) | 13 | 13 | 100.0% | − 8.60 [− 17.63, 0.43] | ||||
Incomplete meta-analysis of neurite length due to Zhang et al. (2014) not having available sample sizes thus an appropriate study size (N = 3) was not reached. The table was produced in RevMan 5.4 with the associated graph, and statistical measures were removed from the image. Abbreviations: SD, standard deviation; CI, confidence interval
Fig. 6Splice variants of human C9orf72 mRNA. An overview of the exons included in the long and short isoforms of C9orf72 and their subcellular localisation. Abbreviations: aa, amino acids; kDa, kilodalton; RNA, ribonucleic acid; V1/2/3, variant 1/2/3